NASDAQ:ALNA

Allena Pharmaceuticals News Headlines

$1.12
-0.02 (-1.75 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.05
Now: $1.12
$1.12
50-Day Range
$1.14
MA: $1.49
$1.74
52-Week Range
$1.07
Now: $1.12
$3.39
Volume1.31 million shs
Average Volume2.08 million shs
Market Capitalization$63.77 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39

Headlines

Allena Pharmaceuticals (NASDAQ ALNA) News Headlines Today

SourceHeadline
Eiger BioPharmaceuticals (NASDAQ:EIGR) and Allena Pharmaceuticals (NASDAQ:ALNA) Head-To-Head SurveyEiger BioPharmaceuticals (NASDAQ:EIGR) and Allena Pharmaceuticals (NASDAQ:ALNA) Head-To-Head Survey
americanbankingnews.com - April 12 at 8:14 PM
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Given Average Rating of "Buy" by BrokeragesAllena Pharmaceuticals, Inc. (NASDAQ:ALNA) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - April 9 at 9:03 AM
Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Expected to Announce Earnings of -$0.20 Per ShareAllena Pharmaceuticals, Inc. (NASDAQ:ALNA) Expected to Announce Earnings of -$0.20 Per Share
americanbankingnews.com - April 9 at 8:22 AM
Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Allena Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - April 8 at 9:45 AM
How Many Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Shares Have Insiders Sold, In The Last Year?How Many Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Shares Have Insiders Sold, In The Last Year?
nasdaq.com - April 7 at 6:10 PM
Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of DirectorsAllena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors
finance.yahoo.com - April 7 at 8:09 AM
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 9 at 8:24 AM
Top Penny Stocks On Robinhood If Biotech Is Your Focus Right NowTop Penny Stocks On Robinhood If Biotech Is Your Focus Right Now
marketwatch.com - February 24 at 10:48 PM
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in MarchAllena Pharmaceuticals to Present at Upcoming Investor Conferences in March
finance.yahoo.com - February 24 at 12:46 PM
Are Institutions Heavily Invested In Allena Pharmaceuticals, Inc.s (NASDAQ:ALNA) Shares?Are Institutions Heavily Invested In Allena Pharmaceuticals, Inc.'s (NASDAQ:ALNA) Shares?
finance.yahoo.com - February 5 at 7:51 AM
Allena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial OfficerAllena Pharmaceuticals Appoints Richard D. Katz, M.D. as Chief Financial Officer
finance.yahoo.com - February 2 at 11:59 AM
Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?Has Allena Pharmaceuticals (ALNA) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - January 12 at 5:27 PM
Allena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the UpgradeAllena Pharmaceuticals, Inc. (ALNA) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - January 12 at 5:27 PM
Allena Pharmaceuticals to Present at Upcoming Investor Conferences in JanuaryAllena Pharmaceuticals to Present at Upcoming Investor Conferences in January
finance.yahoo.com - January 4 at 8:19 AM
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 MillionAllena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
finance.yahoo.com - December 2 at 12:52 AM
Allena Pharmaceuticals announces $10M bought dealAllena Pharmaceuticals announces $10M bought deal
seekingalpha.com - December 1 at 7:51 PM
Allena Pharmaceuticals Announces $10.0 Million Bought Deal OfferingAllena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
finance.yahoo.com - December 1 at 7:51 PM
Allena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical OfficerAllena Pharmaceuticals Announces Appointment of David J. Clark, M.D., M.R.C.P. as Chief Medical Officer
finance.yahoo.com - December 1 at 2:51 PM
Allena Pharmas ALLN-346 shows encouraging action in early-stage studyAllena Pharma's ALLN-346 shows encouraging action in early-stage study
seekingalpha.com - November 30 at 3:45 PM
Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346Allena Pharmaceuticals Announces Initial Data from Phase 1 Trial of ALLN-346
finance.yahoo.com - November 30 at 9:39 AM
Allena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business UpdateAllena Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 9 at 8:32 AM
Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in NovemberAllena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
finance.yahoo.com - November 3 at 9:12 AM
Allena Pharmaceuticals Inc. Reg (0PJ.SG)Allena Pharmaceuticals Inc. Reg (0PJ.SG)
ca.finance.yahoo.com - October 16 at 9:04 AM
What Makes Allena Pharmaceuticals, Inc. (ALNA) a New Buy StockWhat Makes Allena Pharmaceuticals, Inc. (ALNA) a New Buy Stock
nasdaq.com - October 6 at 1:44 PM
Allena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax VenturesAllena Pharmaceuticals Announces $25 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures
marketwatch.com - September 30 at 12:47 PM
Allena Pharma rallies on convertible debt fundingAllena Pharma rallies on convertible debt funding
seekingalpha.com - September 30 at 12:47 PM
Why Allena Pharmaceuticals Is Trading Higher TodayWhy Allena Pharmaceuticals Is Trading Higher Today
benzinga.com - September 30 at 12:47 PM
Allena Pharmaceuticals, Inc. Common Stock (ALNA)Allena Pharmaceuticals, Inc. Common Stock (ALNA)
nasdaq.com - September 10 at 5:53 PM
Allena Pharma advances with its early-stage study for ALLN-346 in hyperuricemiaAllena Pharma advances with its early-stage study for ALLN-346 in hyperuricemia
seekingalpha.com - September 8 at 12:39 PM
Allena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney DiseaseAllena Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial of ALLN-346, in Development for the Treatment of Hyperuricemia in Patients with Gout and Advanced Chronic Kidney Disease
finance.yahoo.com - September 8 at 12:39 PM
Allena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in SeptemberAllena Pharmaceuticals to Present Virtually at Upcoming Investor Conferences in September
finance.yahoo.com - September 3 at 1:49 PM
Allena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business UpdateAllena Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - August 5 at 8:15 AM
Allena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual ConferenceAllena Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
finance.yahoo.com - August 4 at 10:11 AM
Allena Pharma raises bought deal offering to $6.7MAllena Pharma raises bought deal offering to $6.7M
seekingalpha.com - July 28 at 10:55 AM
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 MillionAllena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million
finance.yahoo.com - July 27 at 11:26 PM
Allena Pharma secures $5M capital raiseAllena Pharma secures $5M capital raise
seekingalpha.com - July 27 at 6:26 PM
Allena Pharmaceuticals Announces $5.0 Million Bought Deal OfferingAllena Pharmaceuticals Announces $5.0 Million Bought Deal Offering
finance.yahoo.com - July 27 at 6:26 PM
Hedge Funds Nibbling On Allena Pharmaceuticals, Inc. (ALNA)Hedge Funds Nibbling On Allena Pharmaceuticals, Inc. (ALNA)
finance.yahoo.com - June 15 at 10:37 PM
Allena Pharmaceuticals announces $15M registered direct offeringAllena Pharmaceuticals announces $15M registered direct offering
seekingalpha.com - June 3 at 5:25 PM
Allena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesAllena Pharmaceuticals Announces $15.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
finance.yahoo.com - June 3 at 5:25 PM
Allena Pharmaceuticals to Present at Jefferies Virtual Healthcare ConferenceAllena Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 26 at 12:53 PM
Allena Pharmaceuticals EPS beats by $0.13Allena Pharmaceuticals EPS beats by $0.13
seekingalpha.com - May 13 at 10:03 AM
Allena Pharma +9% on Q1 resultsAllena Pharma +9% on Q1 results
seekingalpha.com - May 13 at 10:03 AM
Allena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 13 at 10:03 AM
Allena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the UpgradeAllena Pharmaceuticals, Inc. (ALNA) Moves to Strong Buy: Rationale Behind the Upgrade
finance.yahoo.com - April 22 at 4:12 PM
Allena Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 16 at 8:59 AM
Allena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care ConferenceAllena Pharmaceuticals to Present at 40th Annual Cowen & Co. Health Care Conference
finance.yahoo.com - February 24 at 8:12 AM
Allena Pharma up 11% premarket on revised design of reloxaliase studyAllena Pharma up 11% premarket on revised design of reloxaliase study
seekingalpha.com - February 12 at 9:00 AM
Allena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric HyperoxaluriaAllena Pharmaceuticals Announces Streamlined Design for URIROX-2, Second Pivotal Clinical Trial of Reloxaliase for Enteric Hyperoxaluria
finance.yahoo.com - February 12 at 9:00 AM
Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with EntericAllena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric
www.bloomberg.com - January 23 at 3:34 AM
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.